CL2017003224A1 - Vacuna contra el virus de la fiebre aftosa (fmdv) de virus vaccinia ankara modificado (mva) recombinante - Google Patents
Vacuna contra el virus de la fiebre aftosa (fmdv) de virus vaccinia ankara modificado (mva) recombinanteInfo
- Publication number
- CL2017003224A1 CL2017003224A1 CL2017003224A CL2017003224A CL2017003224A1 CL 2017003224 A1 CL2017003224 A1 CL 2017003224A1 CL 2017003224 A CL2017003224 A CL 2017003224A CL 2017003224 A CL2017003224 A CL 2017003224A CL 2017003224 A1 CL2017003224 A1 CL 2017003224A1
- Authority
- CL
- Chile
- Prior art keywords
- mva
- fmdv
- virus
- mouth disease
- vaccine against
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
- C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
<p>LA PRESENTE INVENCIÓN HACE REFERENCIA A VECTORES POXVIRALES MODIFICADOS Y A MÉTODOS PARA SU ELABORACIÓN Y USO. EN PARTICULAR, LA INVENCIÓN HACE REFERENCIA A LA VACUNA CON BASE EN EL VIRUS DE VACCINIA ANKARA MODIFICADO (CON BASE EN MVA) RECOMBINANTE CONTRA LA INFECCIÓN POR FMDV Y A PRODUCTOS, MÉTODOS Y USOS RELACIONADOS. ESPECÍFICAMENTE, LA PRESENTE INVENCIÓN HACE REFERENCIA A VECTORES DE MVA GENÉTICAMENTE MODIFICADOS (RECOMBINANTES) QUE COMPRENDEN AL MENOS UNA SECUENCIA DE NUCLEÓTIDOS HETERÓLOGA QUE CODIFICA UN DETERMINANTE ANTIGÉNICO DE UNA PROTEÍNA DE FMDV. LA INVENCIÓN TAMBIÉN HACE REFERENCIA A PRODUCTOS, MÉTODOS Y USOS DE ESTOS, POR EJEMPLO, ADECUADOS PARA INDUCIR UNA RESPUESTA INMUNITARIA PROTECTORA EN UN SUJETO.</p>
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562175738P | 2015-06-15 | 2015-06-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2017003224A1 true CL2017003224A1 (es) | 2018-04-20 |
Family
ID=56321898
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2017003224A CL2017003224A1 (es) | 2015-06-15 | 2017-12-14 | Vacuna contra el virus de la fiebre aftosa (fmdv) de virus vaccinia ankara modificado (mva) recombinante |
Country Status (11)
Country | Link |
---|---|
US (2) | US11103570B2 (es) |
EP (1) | EP3307309A1 (es) |
CN (1) | CN107709554A (es) |
AU (2) | AU2016278806A1 (es) |
BR (1) | BR112017026649A2 (es) |
CA (1) | CA2987159A1 (es) |
CL (1) | CL2017003224A1 (es) |
EA (1) | EA201890042A1 (es) |
MX (1) | MX2017016273A (es) |
WO (1) | WO2016202828A1 (es) |
ZA (1) | ZA201707985B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2016278806A1 (en) * | 2015-06-15 | 2017-12-14 | Bavarian Nordic A/S | Recombinant modified vaccinia virus Ankara (MVA) foot and mouth disease virus (FMDV) vaccine |
WO2018211419A1 (en) | 2017-05-15 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
EP3624851A1 (en) | 2017-05-15 | 2020-03-25 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
US20210187100A1 (en) | 2018-09-06 | 2021-06-24 | Bavarian Nordic A/S | Storage Improved Poxvirus Compositions |
KR20220153587A (ko) | 2020-03-12 | 2022-11-18 | 버베리안 노딕 에이/에스 | 폭스바이러스 안정성을 개선하는 조성물 |
CN111926043A (zh) * | 2020-08-10 | 2020-11-13 | 中国农业科学院兰州兽医研究所 | 共表达fmdv和pprv抗原基因重组病毒的构建方法 |
GB202217045D0 (en) * | 2022-11-15 | 2022-12-28 | Univ Cape Town | Recombinant lsdv vectored foot and mouth disease antigenic constructs |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EE05680B1 (et) * | 2000-11-23 | 2013-10-15 | Bavarian Nordic A/S | Muundatud vaktsiiniaviirus, selle valmistamine ja kasutamine, seda sisaldav farmatseutiline kompositsioon ning vaktsiin |
US7501127B2 (en) * | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
JP4895505B2 (ja) | 2002-05-16 | 2012-03-14 | バヴァリアン・ノルディック・アクティーゼルスカブ | 変異ワクシニアウイルスアンカラ(mva)ゲノム中の挿入部位としての遺伝子間領域 |
WO2006073431A2 (en) * | 2004-06-25 | 2006-07-13 | Merial Limited | Avipox recombinants expressing foot and mouth disease virus genes |
AU2009319336B2 (en) * | 2008-11-27 | 2015-03-26 | Bavarian Nordic A/S | Promoters for recombinant viral expression |
GB0918375D0 (en) * | 2009-10-20 | 2009-12-02 | Animal Health Inst | Construct |
AU2011224188B2 (en) * | 2010-03-12 | 2015-01-22 | Boehringer Ingelheim Animal Health USA Inc. | Bluetongue virus recombinant vaccines and uses thereof |
AU2016278806A1 (en) * | 2015-06-15 | 2017-12-14 | Bavarian Nordic A/S | Recombinant modified vaccinia virus Ankara (MVA) foot and mouth disease virus (FMDV) vaccine |
US10385319B2 (en) * | 2016-09-08 | 2019-08-20 | The Governement of the United States of America, as represented by the Secretary of Homeland Security | Modified foot-and-mouth disease virus 3C proteases, compositions and methods thereof |
-
2016
- 2016-06-15 AU AU2016278806A patent/AU2016278806A1/en not_active Abandoned
- 2016-06-15 CN CN201680033523.3A patent/CN107709554A/zh active Pending
- 2016-06-15 MX MX2017016273A patent/MX2017016273A/es unknown
- 2016-06-15 EA EA201890042A patent/EA201890042A1/ru unknown
- 2016-06-15 EP EP16734206.2A patent/EP3307309A1/en active Pending
- 2016-06-15 US US15/737,028 patent/US11103570B2/en active Active
- 2016-06-15 CA CA2987159A patent/CA2987159A1/en active Pending
- 2016-06-15 BR BR112017026649A patent/BR112017026649A2/pt active Search and Examination
- 2016-06-15 WO PCT/EP2016/063691 patent/WO2016202828A1/en active Application Filing
-
2017
- 2017-11-23 ZA ZA2017/07985A patent/ZA201707985B/en unknown
- 2017-12-14 CL CL2017003224A patent/CL2017003224A1/es unknown
-
2021
- 2021-08-30 US US17/460,641 patent/US20210393766A1/en not_active Abandoned
-
2022
- 2022-07-12 AU AU2022205166A patent/AU2022205166A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
ZA201707985B (en) | 2024-04-24 |
US20210393766A1 (en) | 2021-12-23 |
AU2016278806A1 (en) | 2017-12-14 |
AU2022205166A1 (en) | 2022-08-04 |
US11103570B2 (en) | 2021-08-31 |
US20180185466A1 (en) | 2018-07-05 |
CN107709554A (zh) | 2018-02-16 |
CA2987159A1 (en) | 2016-12-22 |
MX2017016273A (es) | 2018-04-20 |
EP3307309A1 (en) | 2018-04-18 |
BR112017026649A2 (pt) | 2018-08-28 |
EA201890042A1 (ru) | 2018-05-31 |
WO2016202828A1 (en) | 2016-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2017003224A1 (es) | Vacuna contra el virus de la fiebre aftosa (fmdv) de virus vaccinia ankara modificado (mva) recombinante | |
CO2018005258A2 (es) | Vacuna del virus herpes simple | |
BR112017003908A2 (pt) | Vacina contra filovírus de vírus de vaccinia modificado recombinante ankara (mva)? | |
BR112018013387A2 (pt) | vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit | |
CO2019011548A2 (es) | Vacunas contra el gallid herpesvirus 3 recombinante que codifican antígenos patogénicos aviares heterólogos | |
AR105470A1 (es) | Métodos para inducir una respuesta inmune | |
BR112018011122A2 (pt) | antígenos, vetores, composições, e métodos de utilização para o vírus da imunodeficiência humana dos mesmos | |
BR112015002131A8 (pt) | Vírus vaccinia ankara modificado (mva) recombinante, composição farmacêutica e uso do referido mva recombinante | |
BR112019010275A2 (pt) | adenovírus recombinante, composição, uso do adenovírus ou composição, método de induzir uma resposta imune em um paciente, e, adenovírus de símio não humano | |
CY1120430T1 (el) | Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων | |
CL2017001961A1 (es) | Vacuna bivalente contra el virus de gripe porcina | |
BR112015022582A2 (pt) | molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo | |
BR112016015422A2 (pt) | formulações de vacina de frasco único | |
EA201892735A1 (ru) | Состав вакцины против hiv | |
CY1124707T1 (el) | Συνθεσεις και μεθοδοι για την επαγωγη ενισχυμενης ανοσοαποκρισης με χρηση φορεων ιων poxvirus (ευλογοϊων) | |
DOP2024000040A (es) | Vacunas para vhb y métodos de tratamiento de vhb | |
CU24580B1 (es) | Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas | |
CL2021003211A1 (es) | Una cepa viva modificada, del virus del síndrome respiratorio y reproductivo porcino (prrs), vacuna que lo comprende y su uso para tratar el prrs tipo ii. (divisional solicitud no. 2123-2018) | |
CO2017001614A2 (es) | Vacuna en vector recombinante de adenovirus aviar serotipo 9 | |
BR112022011885A2 (pt) | Molécula de ácido nucleico, composição imunogênica, peptídeo, e, métodos para induzir uma resposta imune e para tratar ou prevenir uma patologia | |
AR108014A1 (es) | Vacuna universal para enfermedades virales y método de vacunación | |
CO2022004470A2 (es) | Vectores de herpesvirus de los pavos recombinante que expresan antígenos de patógenos aviares y usos de estos | |
EA200701801A1 (ru) | Применение модифицированных поксвирусов для быстрой индукции иммунитета против поксвирусных или других инфекционных агентов | |
PH12018502436A1 (en) | Multivalent vaccines major swine viral diseases | |
AR104271A1 (es) | Vacuna contra las paperas en base al virus jeryl lynn 2 recombinante |